About
Equillium develops immunology-based therapies targeting severe autoimmune and inflammatory diseases with novel modalities including multi-cytokine inhibitory peptides and AhR modulators; its clinical pipeline includes treatments for acute Graft-Versus-Host Disease, asthma, and lupus nephritis.
Explore Equillium's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.